KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q3 2017 13F Holders as of 30 Sep 2017
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 7,715,060
- Share change
- +346,622
- Total reported value
- $52,230,000
- Price per share
- $6.73
- Number of holders
- 15
- Value change
- +$2,314,839
- Number of buys
- 6
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
|
Company |
5.7%
|
2,901,927
|
$21,358,000 | — | 30 Jun 2017 | |
| SV Health Investors, LLC |
13F
|
Company |
5.1%
|
2,579,490
|
$18,985,000 | — | 30 Jun 2017 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.2%
|
591,070
|
$4,350,000 | — | 30 Jun 2017 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.65%
|
329,942
|
$2,428,000 | — | 30 Jun 2017 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.64%
|
322,436
|
$2,276,000 | — | 30 Jun 2017 | |
| VHCP Management II, LLC |
13F
|
Company |
0.44%
|
221,651
|
$1,631,000 | — | 30 Jun 2017 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.38%
|
189,900
|
$1,367,000 | — | 30 Jun 2017 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.36%
|
180,872
|
$1,303,000 | — | 30 Jun 2017 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
21,665
|
$159,000 | — | 30 Jun 2017 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.02%
|
10,984
|
$81,000 | — | 30 Jun 2017 | |
| FIRST QUADRANT LLC/CA |
13F
|
Company |
0.02%
|
10,850
|
$80,000 | — | 30 Jun 2017 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.01%
|
4,331
|
$32,000 | — | 30 Jun 2017 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,506
|
$11,000 | — | 30 Jun 2017 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
905
|
$7,000 | — | 30 Jun 2017 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0%
|
608
|
$4,000 | — | 30 Jun 2017 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0%
|
306
|
$3,000 | — | 30 Jun 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
159
|
$1,000 | — | 30 Jun 2017 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2017
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2017 vs Q2 2017 Across Filers
| Investor | Q2 2017 Shares | Q3 2017 Shares | Share Diff | Share Chg % | Q2 2017 Value $ | Q3 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.